[Ip-health] KEI Appeals NIH/NCI Decision to Proceed with License of CD30 CAR T technology to Gilead/Kite

Andrew Goldman andrew.goldman at keionline.org
Tue Feb 27 07:20:16 PST 2018

KEI has appealed the NIH/NCI decision to proceed with the proposed
exclusive license of anti-CD30 CAR T technology to Gilead.

We have posted a blog on this appeal here: https://www.keionline.org/26686

The appeal itself is available here:

However, NIH wrote to say that they would reject the appeal even before it
was filed. We submitted the appeal formally, and requested that they
reconsider that decision.

Andrew S. Goldman
Counsel, Policy and Legal Affairs
Knowledge Ecology International
andrew.goldman at keionline.org // www.twitter.com/ASG_KEI
tel.: +1.202.332.2670 <(202)%20332-2670>

More information about the Ip-health mailing list